Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Briefing
  • Published:

A vaccine to treat ALK+ lung cancer and prevent metastatic disease

Nature Cancer volume 4, pages 933–934 (2023)Cite this article

Subjects

Tyrosine kinase inhibitors that target anaplastic lymphoma kinase (ALK) have greatly improved the survival of patients with ALK-rearranged non-small-cell lung cancer, but they are insufficient to achieve a complete cure. A newly developed vaccine elicited a strong immune response specifically against ALK that eradicated primary tumors and prevented the onset of metastatic disease in mice.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: The ALK vaccine cures ALK+ NSCLC tumors in mice and prevents their metastatic spread.

References

  1. Chiarle, R., Voena, C., Ambrogio, C., Piva, R. & Inghirami, G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat. Rev. Cancer 8, 11–23 (2008). A review article that describes the biology of ALK-driven cancers.

    Article  CAS  PubMed  Google Scholar 

  2. Schneider, J. L., Lin, J. J. & Shaw, A. T. ALK-positive lung cancer: a moving target. Nat. Cancer 4, 330–343 (2023). A review article that describes the state of the art for therapy and targeting resistance in patients with ALK-rearranged NSCLC.

    Article  CAS  PubMed  Google Scholar 

  3. Voena, C. et al. Efficacy of a cancer vaccine against ALK-rearranged lung tumors. Cancer Immunol. Res. 3, 1333–1343 (2015). This paper reports the efficacy of a DNA-based vaccine in a transgenic model of ALK-rearranged lung cancer.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Liu, H. et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature 507, 519–522 (2014). This paper reports a method to potently increase the immunogenicity of peptide-based cancer vaccines.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Mahadevan, N. R. et al. Intrinsic immunogenicity of small cell lung carcinoma revealed by its cellular plasticity. Cancer Discov. 11, 1952–1969 (2021). This paper reports approaches and drugs that can be used to increase the expression of MHC-I molecules in cancer cells.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Mota, I. et al. ALK vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer. Nat. Cancer https://doi.org/10.1038/s43018-023-00591-2 (2023).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

A vaccine to treat ALK+ lung cancer and prevent metastatic disease. Nat Cancer 4, 933–934 (2023). https://doi.org/10.1038/s43018-023-00592-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-023-00592-1

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing